Сайта е предназначен за медицински специалисти

Около 40 милиона в световен мащаб страдат от розацея1
Според други данни между 10-22% от населението е засегнато2

Референции

  1. Shanler S, Ondo A. Successful treatment of the erythema and flushing of rosacea using a topically applied selective a1 adrenergic receptor agonist, oxymetazoline [abstract taken from J Am Acad Dermatol. 2008;58(2):AB9]. Presented at: American Academy of Dermatology 66th Annual Meeting; February 1-5, 2008; San Antonio, TX.
  2. Dirschka T. Perceptions on the Psychological Impact of Facial Erythema Associated with Rosacea: Results of International Survey. Dermatol Ther; 2015. Published online: DOI 10.1007/s13555-015-0077-2
  3. Blount BW, Pelletier, AL. Rosacea: A Common, Yet Commonly Overlooked, Condition. Am Fam Phys, 2002;66(3):435-40.
  4. National Rosacea Society: Survey shows controlling stress can reduce flare-up frequency. Available at: http://www.rosacea.org/rr/2011/fall/article_3.php (Last accessed July 2015)
  5. National Rosacea Society: New Rosacea Survey Shows Emotional Toll of Facial Redness Equals Impact of Bumps, Pimples. Available at: http://www.rosacea.org/press/new-rosacea-survey-shows-emotional-toll-facial-redness-equals-impact-bumps-pimples (Last accessed July 2015)
  6. National Rosacea Society: Rosacea Takes Toll on Sufferers in the Workplace, Survey Shows. Available at: http://rosacea.org/press/archive/20110601.php (Last accessed July 2015)
  7. National Rosacea Society: Rosacea Patients Feel Effects of Their Condition in Social Settings. Available at: http://rosacea.org/rr/2012/fall/article_3.php (Last accessed July 2015)